Epidermal growth factor receptor in lung cancer: The amazing interplay of molecular testing and cytology

Cancer Cytopathology

Volumn 121, Issue 10, 2013, Pages 540-543

  Idowu, Michael O ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

CANCER STAGING; CYTOLOGY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; MEASUREMENT ACCURACY; MIXED TUMOR; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SOMATIC MUTATION; CYTODIAGNOSIS; FEMALE; GENETICS; LUNG TUMOR; MALE; MUTATION; NON SMALL CELL LUNG CANCER; LUNG NON SMALL CELL CANCER; NOTE;

CARCINOMA, NON-SMALL-CELL LUNG; CYTODIAGNOSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891526702     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21321     Document Type: Review

References (20)

1. Cohen S, Carpenter G. Human epidermal growth factor: isolation and chemical and biologic properties. Proc Natl Acad Sci U S A. 1975;72: 1317-1321.
2. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48: 193-216.
3. Sqambato A, Casaluce F, Maione P, et al. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced nonsmall cell lung cancer patients harboring EGFR mutations. Curr Med Chem. 2012;19: 3337-3352.
4. Hirsch FR, Janne PA, Eberhardt WE, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013;8: 373-384.
5. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31: 1039-1049.
6. Malapelle U, Bellevicine C, De Luca C, et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung cancer patients. Cancer Cytopathol. 2013;121: 552-560.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Nonsmall cell lung cancer, version 2.2013-pg 66 MS-6; pg 81 MS-21}. Available at: www.nccn.org=professionals= physicians-gls=f-guidelines.asp. Accessed June 3, 2013.
8. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association of Molecular Pathology [published online ahead of print April 4, 2013]. J Mol Diagn. 2013.
9. Clinical and Laboratory Standards Institute (CLSI). Molecular Methods for Clinical Genetics and Oncology Testing: Approved Guideline. 3rd ed. CLSI Document MM01-A3. Wayne, PA: CLSI; 2012.
10. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer=American Thoracic Society=European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137: 668-684.
11. Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 suppl): 131S-148S.
12. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6: 451-458.
13. Wong C, DiCioccio RA, Allen HJ, et al. Mutations in BRCA1 from formalin-fixed, paraffin-embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet. 1998;107: 21-27.
14. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation in of archival specimens. Am J Pathol. 199;155: 1467-1471.
15. Akbari N, Hansen MD, Halgunset J, et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn. 2005;7: 36-39.
16. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol. 2013;41: 316-323.
17. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011;119: 80-91.
18. Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn. 2011; 11: 333-343.
19. Buttitta F, Felicioni LDel Grammastro M, et al. Effective assessment of EGFR mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res. 2013;19: 691-698.
20. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinibsensitive ALK rearrangement in a patient with metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7: e14-e16.